Insider Selling: Penumbra (NYSE:PEN) Director Sells 186 Shares of Stock

Key Points

• Penumbra Director Thomas Wilder sold 186 shares of stock at an average price of $253.93, resulting in a total transaction value of $47,230.98, marking a 50% decrease in his holdings.
• The company's latest quarterly earnings showed an EPS of $0.86, exceeding analysts' expectations, with a revenue of $339.46 million, reflecting a 13.4% year-over-year growth.
• Wall Street analysts currently have a Moderate Buy rating on Penumbra, with a consensus target price of approximately $302.93 per share.

Penumbra, Inc. (NYSE:PEN - Get Free Report) Director Thomas Wilder sold 186 shares of the company's stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $253.93, for a total value of $47,230.98. Following the completion of the transaction, the director directly owned 186 shares in the company, valued at $47,230.98. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Thomas Wilder also recently made the following trade(s):

• On Tuesday, August 12th, Thomas Wilder sold 372 shares of Penumbra stock. The stock was sold at an average price of $240.16, for a total value of $89,339.52.

Penumbra Price Performance

NYSE:PEN traded up $2.56 during trading hours on Friday, reaching $256.05. 362,538 shares of the company were exchanged, compared to its average volume of 442,705. The company has a market capitalization of $9.99 billion, a P/E ratio of 68.10, a P/E/G ratio of 2.29 and a beta of 0.41. Penumbra, Inc. has a 1-year low of $190.08 and a 1-year high of $310.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 4.04. The business has a 50 day moving average of $257.64 and a 200 day moving average of $262.97.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.81 by $0.05. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The business had revenue of $339.46 million for the quarter, compared to the consensus estimate of $327.37 million. During the same quarter in the prior year, the business posted $0.64 earnings per share. The firm's quarterly revenue was up 13.4% compared to the same quarter last year. Penumbra has set its FY 2025 guidance at EPS. Research analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current year.

Hedge Funds Weigh In On Penumbra

Hedge funds have recently added to or reduced their stakes in the stock. Synergy Investment Management LLC acquired a new position in Penumbra during the 1st quarter valued at about $27,000. First Horizon Advisors Inc. boosted its stake in Penumbra by 404.8% during the 1st quarter. First Horizon Advisors Inc. now owns 106 shares of the company's stock valued at $28,000 after purchasing an additional 85 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new position in shares of Penumbra during the 2nd quarter worth approximately $30,000. Parkside Financial Bank & Trust lifted its position in shares of Penumbra by 70.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 160 shares of the company's stock worth $41,000 after buying an additional 66 shares in the last quarter. Finally, State of Wyoming bought a new position in shares of Penumbra during the 2nd quarter worth approximately $64,000. Institutional investors and hedge funds own 88.88% of the company's stock.

Wall Street Analyst Weigh In

PEN has been the subject of several recent analyst reports. Canaccord Genuity Group set a $350.00 target price on Penumbra and gave the stock a "buy" rating in a research note on Wednesday, July 30th. Morgan Stanley increased their price objective on Penumbra from $260.00 to $266.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Evercore ISI assumed coverage on Penumbra in a report on Tuesday, September 2nd. They issued an "outperform" rating and a $300.00 price objective for the company. Truist Financial set a $310.00 price objective on Penumbra and gave the company a "buy" rating in a report on Wednesday, July 30th. Finally, Robert W. Baird increased their price objective on Penumbra from $283.00 to $285.00 and gave the company an "outperform" rating in a report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $302.93.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.